Moderna, Inc MRNA Stock Price, Quote & News
Merck desperately needs Moderna’s mRNA-based Personal Cancer Vaccines (“PCVs”) to extend KEYTRUDA’s patent protection beyond 2028. Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. Eva Ados, ERshares COO and chief investment strategist, joins CNBC’s ‘Power Lunch’ to share outlooks on three stocks. …